Keiichi Fujiwara, MD, PhD
Articles
POINT: Is There Still a Role for Intraperitoneal Platinum Therapy in Ovarian Cancer?
February 15th 2018Intraperitoneal (IP) chemotherapy is a reasonable treatment approach for ovarian cancer because it can directly expose the surface tissues to which the cancer has disseminated to an extremely high concentration of the chemotherapy drug.
Use of IP Chemotherapy in Ovarian Cancer: The Critical Questions
February 21st 2011The article by Dr. Echarri Gonzalez and her colleagues regarding intraperitoneal (IP) chemotherapy for women with epithelial ovarian cancer provides a comprehensive yet practical review of the critical questions surrounding the use of IP chemotherapy.
Latest Updated Articles
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Published: August 19th 2019 | Updated: November 21st 2024
A 22-Year-Old Woman With Pain, Tenderness and Swelling in the Breast
Published: July 29th 2015 | Updated: November 21st 2024
Liver Abnormality in 28-Year-Old Patient
Published: November 8th 2024 | Updated: November 21st 2024
The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural Effusion
